Literature DB >> 24356332

Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapy.

Holly J Engelstad1, Robert D Roghair, Chadi A Calarge, Tarah T Colaizy, Scott Stuart, Sarah E Haskell.   

Abstract

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed psychotropics for major depressive disorder during pregnancy and are used in up to 6.2% of pregnancies.
OBJECTIVE: To compare the perinatal outcomes of pregnancies complicated by maternal depression with or without SSRI therapy versus nondepressed pregnancies.
METHODS: International Classification of Diseases (ICD)-9 codes for depression were identified among women who delivered at the University of Iowa from April 2009 to March 2011. Data were extracted from linked maternal-neonatal records for all charts with an ICD-9 code for depression and an equal number of women without ICD-9 codes for depression.
RESULTS: Of the 3,695 women who delivered between 2009 and 2011, 238 had an ICD-9 code for depression. Sixteen women had depression listed in their records but did not have an ICD-9 code for depression. Their data were combined with those of the women with ICD-9 codes for depression, and it was found that 126 women (50%) in this combined depression cohort received an SSRI. Women with depression had increased alcohol and tobacco use, BMI and premature delivery rates (p < 0.01). Maternal depression was associated with an increased frequency of neonatal intensive care unit (NICU) admission (p < 0.001). In addition to depression, maternal SSRI use, obesity and smoking were univariate predictors of NICU admission.
CONCLUSIONS: Among women with depression, the use of an SSRI was not associated with significant differences in any of the measured maternal or neonatal parameters, but further studies are needed to evaluate the specific effects of SSRI exposure in early or late gestation. Despite SSRI utilization, women with depression continue to have increased risks during pregnancy.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24356332      PMCID: PMC4054700          DOI: 10.1159/000356774

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  26 in total

1.  Neonate characteristics after maternal use of antidepressants in late pregnancy.

Authors:  Bengt Källén
Journal:  Arch Pediatr Adolesc Med       Date:  2004-04

2.  Antidepressant drugs during pregnancy and infant congenital heart defect.

Authors:  Bengt Källén; Petra Otterblad Olausson
Journal:  Reprod Toxicol       Date:  2006-01-06       Impact factor: 3.143

3.  Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Authors:  Tim F Oberlander; William Warburton; Shaila Misri; Jaafar Aghajanian; Clyde Hertzman
Journal:  Arch Gen Psychiatry       Date:  2006-08

4.  Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.

Authors:  N A Kulin; A Pastuszak; S R Sage; B Schick-Boschetto; G Spivey; M Feldkamp; K Ormond; D Matsui; A K Stein-Schechman; L Cook; J Brochu; M Rieder; G Koren
Journal:  JAMA       Date:  1998-02-25       Impact factor: 56.272

5.  Delivery outcome after the use of antidepressants in early pregnancy.

Authors:  A Ericson; B Källén; B Wiholm
Journal:  Eur J Clin Pharmacol       Date:  1999-09       Impact factor: 2.953

6.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

7.  The impact of depression and fluoxetine treatment on obstetrical outcome.

Authors:  R Suri; L Altshuler; V Hendrick; N Rasgon; E Lee; J Mintz
Journal:  Arch Womens Ment Health       Date:  2004-06-17       Impact factor: 3.633

8.  Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.

Authors:  Philip Sanford Zeskind; Laura E Stephens
Journal:  Pediatrics       Date:  2004-02       Impact factor: 7.124

9.  Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.

Authors:  Rachel Levinson-Castiel; Paul Merlob; Nehama Linder; Lea Sirota; Gil Klinger
Journal:  Arch Pediatr Adolesc Med       Date:  2006-02

10.  Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

Authors:  Christina D Chambers; Sonia Hernandez-Diaz; Linda J Van Marter; Martha M Werler; Carol Louik; Kenneth Lyons Jones; Allen A Mitchell
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

View more
  4 in total

1.  A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns.

Authors:  Deidra A Ansah; Benjamin E Reinking; Tarah T Colaizy; Robert D Roghair; Sarah E Haskell
Journal:  Neonatology       Date:  2019-03-05       Impact factor: 4.035

2.  MTHFR genetic polymorphism increases the risk of preterm delivery.

Authors:  Yanrong Nan; Hongmei Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero.

Authors:  Christopher W Hooper; Cassidy Delaney; Taylor Streeter; Michael T Yarboro; Stanley Poole; Naoko Brown; James C Slaughter; Robert B Cotton; Jeff Reese; Elaine L Shelton
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-01       Impact factor: 4.733

4.  Genetic Association of Angiotensin-Converting Enzyme (ACE) Gene I/D Polymorphism with Preterm Birth in Korean Women: Case-Control Study and Meta-Analysis.

Authors:  Noo Ri Lee; In Wook Hwang; Hyung Jun Kim; Yun Dan Kang; Jin Wan Park; Han Jun Jin
Journal:  Medicina (Kaunas)       Date:  2019-06-10       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.